biostudies-literatureUnknown8(1)Desai JBeiGene, Ltd.<h4>Background</h4>The programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) axis plays a central role in suppressing antitumor immunity; axis dysregulation can be used by cancer cells to evade the immune system. Tislelizumab, an investigational monoclonal antibody with high affinity and binding specificity for PD-1, was engineered to minimize binding to FcγR on macrophages to limit antibody-dependent phagocytosis, a potential mechanism of resistance to anti-PD-1 therapy. The aim of this phase IA/IB study was to investigate the safety/tolerability, antitumor effects and optimal dose and schedule of tislelizumab in patients with advanced solid tumors.<h4>Methods</h4>Patients (aged ≥18 years) enrolled in phase IA received intravenous tislelizumab 0.5, 2, 5 or 10 mg/kg every 2 wJournal for immunotherapy of cancere000453https://www.ebi.ac.uk/biostudies/studies/S-EPMC7295442biostudies-literaturePhase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors.PMC7295442Millward MSandhu SWu JLin CCRau KMDesai JBarlow PLee JSKang YKHill AChao YPaton VLu CHLiang LMarkman BYen CJHorvath LWu CYDeva SKeam BJameson MFriedlander MZhang YHou MMLee KHfalsePhase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors.<h4>Background</h4>The programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) axis plays a central role in suppressing antitumor immunity; axis dysregulation can be used by cancer cells to evade the immune system. Tislelizumab, an investigational monoclonal antibody with high affinity and binding specificity for PD-1, was engineered to minimize binding to FcγR on macrophages to limit antibody-dependent phagocytosis, a potential mechanism of resistance to anti-PD-1 therapy. The aim of this phase IA/IB study was to investigate the safety/tolerability, antitumor effects and optimal dose and schedule of tislelizumab in patients with advanced solid tumors.<h4>Methods</h4>Patients (aged ≥18 years) enrolled in phase IA received intravenous tislelizumab 0.5, 2, 5 or 10 mg/kg every 2 w2020-01-01T00:00:00Z2020 Jun2026-06-15T06:07:23.234Z2026-06-15T03:08:06.799ZS-EPMC72954423254085810.1136/jitc-2019-000453